Burkholderia pseudomallei Infections (Melioidosis) – Pipeline Review, H2, Pharmaceutical 2016

| December 28, 2016

article image
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Burkholderia pseudomallei Infections (Melioidosis).

Spotlight

Butterworth Laboratories

Excellence in Analytical Chemistry Since 1974 With 40 years experience, Butterworth Laboratories remains a fully independent UK contract analytical service providing Quality Control Testing, Method Development & Validation and Stability Study Storage & Testing to the pharmaceutical and related industries. We work in partnership with our clients who not only recognise our expertise in analytical chemistry and standards of service but also value our integrity and impartiality. Our regular inspections by the MHRA, UKAS and FDA ensure that the service you receive is at the very highest level for testing, validation and analysis.

OTHER ARTICLES

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | February 25, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Butterworth Laboratories

Excellence in Analytical Chemistry Since 1974 With 40 years experience, Butterworth Laboratories remains a fully independent UK contract analytical service providing Quality Control Testing, Method Development & Validation and Stability Study Storage & Testing to the pharmaceutical and related industries. We work in partnership with our clients who not only recognise our expertise in analytical chemistry and standards of service but also value our integrity and impartiality. Our regular inspections by the MHRA, UKAS and FDA ensure that the service you receive is at the very highest level for testing, validation and analysis.

Events